| Bioactivity | ETD001 is a long-acting ENaC inhibitor, with an IC50 of 57.5 nM in cultured HBE cells. ETD001 can be used in the study for cystic fibrosis[1][2]. |
| CAS | 2227484-71-9 |
| Formula | C41H57F6N9O16 |
| Molar Mass | 1045.93 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Henry Danahay, et al. Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis. Eur J Med Chem. 2025 Jan 15:282:117040. [2]. Henry Danahay, et al. ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo. J Cyst Fibros. 2024 Jun 7:S1569-1993(24)00081-X. |
ETD001
CAS: 2227484-71-9 F: C41H57F6N9O16 W: 1045.93
ETD001 is a long-acting ENaC inhibitor, with an IC50 of 57.5 nM in cultured HBE cells.ETD001 can be used in the study fo
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.